PMID- 28667483
OWN - NLM
STAT- MEDLINE
DCOM- 20180427
LR  - 20220316
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Linking)
VI  - 255
IP  - 9
DP  - 2017 Sep
TI  - Is ellipsoid zone integrity essential for visual recovery in myopic 
      neovascularization after anti-VEGF therapy?
PG  - 1713-1720
LID - 10.1007/s00417-017-3706-x [doi]
AB  - PURPOSE: To evaluate functional prognostic factors and neuroretinal changes after 
      anti-vascular endothelial growth factor (VEGF) treatment in patients with naive, 
      recent myopic neovascularization (mCNV), as assessed by spectral-domain optical 
      coherence tomography (SD-OCT). METHODS: Specific changes in tomographic features 
      between baseline and final follow-up were retrospectively evaluated by two 
      examiners independently. Imaging was obtained by a multi-modal imaging system 
      which combines fluorescein angiography and SD-OCT. RESULTS: Twenty-two eyes 
      (male, six; female, 16; mean age, 65 +/- 14 years) were considered. Mean follow-up 
      was 21.5 +/- 14 months. Best-corrected visual acuity (BCVA) improved from 
      0.38 +/- 0.26 to 0.16 +/- 0.20 logMAR (p < 0.001). The ellipsoid zone and the 
      external limiting membrane (ELM) were disrupted in 21 (95.5%) and 15 (68.2%) eyes 
      at baseline, and in 16 (72.7%) and nine (40.9%) eyes after therapy respectively. 
      The ellipsoid zone and ELM were typically intact at lesion margins in 13 (59.1%) 
      and 19 eyes (86.5%) respectively at baseline. The inner retina was intact in 20 
      eyes (91%). Six eyes (27.3%) exhibited complete regression without fibrosis. 
      Absence of hemorrhage and integrity of lesion-adjacent ELM and of lesion-adjacent 
      ellipsoid zone at baseline were factors for better final BCVA (p </= 0.05) 
      CONCLUSION: Vision gain might occur despite ellipsoid zone or ELM restoration. 
      Hemorrhage could be considered a negative prognostic factor, integrity of 
      lesion-adjacent ELM and of lesion-adjacent ellipsoid zone as positive prognostic 
      factors. Myopic CNV can also resolve completely without fibrosis.
FAU - Milani, Paolo
AU  - Milani P
AD  - Ophthalmology Department, Istituto Auxologico Italiano, Via Stefini 10, 20125, 
      Milan, Italy. dottpaolomilani@hotmail.com.
FAU - Pellegrini, Marco
AU  - Pellegrini M
AD  - Eye Clinic, Biomedical and Clinical Sciences Department, Luigi Sacco Hospital, 
      University of Milan, Milan, Italy.
FAU - Massacesi, Amedeo
AU  - Massacesi A
AD  - Ophthalmology Department, Istituto Auxologico Italiano, Via Stefini 10, 20125, 
      Milan, Italy.
FAU - Moschini, Stefania
AU  - Moschini S
AD  - Ophthalmology Department, Istituto Auxologico Italiano, Via Stefini 10, 20125, 
      Milan, Italy.
FAU - Setaccioli, Marco
AU  - Setaccioli M
AD  - Ophthalmology Department, Istituto Auxologico Italiano, Via Stefini 10, 20125, 
      Milan, Italy.
FAU - Soranna, Davide
AU  - Soranna D
AD  - Statistics and Quantitative Methods Department, University of Milano-Bicocca and 
      Istituto Auxologico Italiano, Milan, Italy.
FAU - Zambon, Antonella
AU  - Zambon A
AD  - Statistics and Quantitative Methods Department, University of Milano-Bicocca and 
      Istituto Auxologico Italiano, Milan, Italy.
FAU - Bottoni, Ferdinando
AU  - Bottoni F
AD  - Eye Clinic, Biomedical and Clinical Sciences Department, Luigi Sacco Hospital, 
      University of Milan, Milan, Italy.
FAU - Bergamini, Fulvio
AU  - Bergamini F
AD  - Ophthalmology Department, Istituto Auxologico Italiano, Via Stefini 10, 20125, 
      Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170630
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Aged
MH  - Angiogenesis Inhibitors
MH  - Bevacizumab/*administration & dosage
MH  - Choroidal Neovascularization/diagnosis/*drug therapy/physiopathology
MH  - Female
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Fundus Oculi
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Myopia, Degenerative/*complications/physiopathology
MH  - *Recovery of Function
MH  - Retinal Ganglion Cells/drug effects/*pathology
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence/*methods
MH  - Treatment Outcome
MH  - Vascular Endothelial Growth Factor A
MH  - Visual Acuity/*physiology
OTO - NOTNLM
OT  - Anti-VEGF
OT  - Ellipsoid zone
OT  - External limiting membrane
OT  - Fluorescein angiography
OT  - Myopia
OT  - Myopic neovascularization
OT  - Neuroretina
OT  - Optical coherence tomography
OT  - Pathologic myopia
OT  - SD-OCT
EDAT- 2017/07/02 06:00
MHDA- 2018/04/28 06:00
CRDT- 2017/07/02 06:00
PHST- 2017/03/03 00:00 [received]
PHST- 2017/05/30 00:00 [accepted]
PHST- 2017/05/15 00:00 [revised]
PHST- 2017/07/02 06:00 [pubmed]
PHST- 2018/04/28 06:00 [medline]
PHST- 2017/07/02 06:00 [entrez]
AID - 10.1007/s00417-017-3706-x [pii]
AID - 10.1007/s00417-017-3706-x [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2017 Sep;255(9):1713-1720. doi: 
      10.1007/s00417-017-3706-x. Epub 2017 Jun 30.